|
WO2020206078A1
|
|
Antidepressants for the treatment or prevention of memory loss and/or cognitive decline or dysfunction in aging
|
|
WO2020168196A1
|
|
Blood-based screen for detecting neurological diseases in primary care settings
|
|
US2019219599A1
|
|
Blood-based screen for detecting neurological diseases in primary care settings
|
|
EP3740761A1
|
|
Companion diagnostic for nsaids and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease
|
|
US2019292156A1
|
|
Deterrents for arthropods and marine organisms
|
|
WO2018013568A1
|
|
Treatment for glaucoma and other eye diseases
|
|
WO2017223291A1
|
|
Blood test for screening out amyloid and alzheimer's disease presence
|
|
US2018020947A1
|
|
Methods and tools for diagnosing insulin resistance and assessing health status using nmr relaxation times for water
|
|
US2015202337A1
|
|
Iron garnet nanoparticles for cancer radiotherapy and chemotherapy
|
|
EP3074525A1
|
|
Personalized medicine approach for treating cognitive loss
|
|
EP3022560A1
|
|
Blood-based screen for detecting neurological diseases in primary care settings
|
|
AU2008240155A1
|
|
Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics
|
